Kodiak Sciences Inc.
About Kodiak Sciences Inc.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$230.0M
- Total assets
- $351.5M
- Market cap
- $1.9B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $234.4M
- Operating income
- -$234.4M
- Income tax
- $52.0K
- Net income
- -$230.0M
- EPS (basic)
- $-4.32
- EPS (diluted)
- $-4.32
Balance sheet
- Total assets
- $351.5M
- Current assets
- $214.8M
- Total liabilities
- $194.2M
- Current liabilities
- $45.5M
- Shareholders’ equity
- $157.4M
Cash flow
- Operating cash flow
- -$136.0M
- Investing cash flow
- -$506.0K
- Financing cash flow
- $178.3M
- Net cash flow
- $41.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.9B
- EPS (diluted)
- $-4.32
- Shares outstanding
- 65.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 4, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $230.0M.
- Trading 36% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Kodiak Sciences Inc..
Write a review
News about Kodiak Sciences Inc.
News & sentiment via Polygon.io
